Sugi Predict

Sugi Predict / Compounds / SCHEMBL1004574

SCHEMBL1004574

SCHEMBL1004574

Cc1cccc(C)c1CC(=O)O

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.58
▸ GAA P10253 2/20 0.58
▸ MAPT P10636 2/20 0.58
▸ MEN1 O00255 1/20 0.58
▸ KMT2A Q03164 1/20 0.58
▸ AKR1B1 P15121 2/20 0.56
▸ SLC22A12 Q96S37 7/20 0.51
▸ PTGS2 P35354 3/20 0.49
▸ SMN1; SMN2 Q16637 3/20 0.47
▸ ALDH1A1 P00352 2/20 0.47
▸ CYP1A2 P05177 1/20 0.47
▸ CYP3A4 P08684 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ CASP1 P29466 1/20 0.47
▸ CASP7 P55210 1/20 0.47
▸ HPGD P15428 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7911305 0.87 PTGS2 (0.56) KDM4EGAAMAPTMEN1KMT2A
SCHEMBL28474465 0.87 KDM4E (0.51) KDM4EGAAMAPTMEN1KMT2A
SCHEMBL2047862 0.87 KDM4E (0.51) KDM4EGAAMAPTMEN1KMT2A
SCHEMBL27373218 0.86 KDM4E (0.50) KDM4EGAAMAPTMEN1KMT2A
SCHEMBL29101389 0.86 KDM4E (0.50) KDM4EGAAMAPTMEN1KMT2A
SCHEMBL2340668 0.86 KDM4E (0.55) KDM4EGAAMAPTMEN1KMT2A
SCHEMBL28153560 0.86 KDM4E (0.50) KDM4EGAAMAPTMEN1KMT2A
SCHEMBL30755273 0.86 KDM4E (0.50) KDM4EGAAMAPTMEN1KMT2A
SCHEMBL3044981 0.86 AKR1B1 (0.74) KDM4EGAAMAPTMEN1KMT2A
SCHEMBL2552936 0.86 PTGS2 (0.54) KDM4EGAAMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103980109-B Process for preparing (2, 4-dimethylbiphenyl-3-yl) acetic acid, esters thereof and intermediate compounds 拜尔农作物科学股份公司 2017-05-03 — — CN claimed
US-7723333-B2 Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators ASTRAZENECA AB (SE) 2010-05-25 — — US claimed
US-20090005353-A1 Non-Anilinic Derivatives of Isothiazol-3(2H)-one 1,1-Dioxides as Liver X Receptor Modulators ASTRAZENECA AB (SE) 2009-01-01 — — US claimed
EP-4702033-A1 DESMURAMYLPEPTIDE DIACIDS AS NOD2 AGONISTS AND USE THEREOF Imhotex Limited (GB) 2026-03-04 — — EP disclosed
WO-2025068452-A1 GUANFACINE DERIVATIVES AND THEIR USE IN TREATING CANCER NEGIO THERAPEUTICS (BE) 2025-04-03 — — WO disclosed
WO-2024224086-A1 DESMURAMYLPEPTIDE DIACIDS AS NOD2 AGONISTS AND USE THEREOF Imhotex Limited (GB) 2024-10-31 — — WO disclosed
US-20230338314-A1 METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS THE ROCKEFELLER UNIVERSITY (US) 2023-10-26 — — US disclosed
US-11691938-B2 Process for preparing 2,6-dialkylphenylacetic acids BAYER AKTIENGESELLSCHAFT (DE) 2023-07-04 — — US disclosed
US-11691938-B2 Process for preparing 2,6-dialkylphenylacetic acids BAYER AKTIENGESELLSCHAFT (DE) 2023-07-04 — — US disclosed
US-11691938-B2 Process for preparing 2,6-dialkylphenylacetic acids BAYER AKTIENGESELLSCHAFT (DE) 2023-07-04 — — US disclosed
US-11648220-B2 Methods for the treatment of myeloid derived suppressor cells related disorders THE ROCKEFELLER UNIVERSITY (US) 2023-05-16 — — US disclosed
EP-0391030-A2 Polyphenylene ether-polycondensate-block copolymers and process for their preparation HÜLS AKTIENGESELLSCHAFT (DE) 1990-10-10 — — EP disclosed
EP-0391031-A2 Block copolymers based on polyphenylene ethers and polycondensates, and a process for their preparation HÜLS AKTIENGESELLSCHAFT (DE) 1990-10-10 — — EP disclosed
US-4882316-A CONTROL AND PREVENTION OF VIRAL INFECTIONS HOFFMANN-LA ROCHE INC. (US) 1989-11-21 — — US disclosed
EP-0338209-A2 Thermoplastic molding masses on the basis of functionalized polyphenylenethers and polyamides HÜLS AKTIENGESELLSCHAFT (DE) 1989-10-25 — — EP disclosed
EP-0255894-A2 Pyrimidine derivatives, their preparation and medicaments containing them F. HOFFMANN-LA ROCHE AG (CH) 1988-02-17 — — EP disclosed
US-4440940-A HYPOLIPIDEMIC AND ANTIATHEROSCLEROTIC AGENTS AMERICAN CYANAMID COMPANY (US) 1984-04-03 — — US disclosed
US-4281019-A 4-[(Unsaturated or cyclopropylated alkyl)amino]phenyl compounds useful as hypolipidemic and antiatherosclerotic agents AMERICAN CYANAMID COMPANY (US) 1981-07-28 — — US disclosed
US-4203896-A WITH MERCURIC ACETATE AND ACETIC ACID, ACIDIC HYDROLYSIS OF N-PROPENYL GROUP ELI LILLY AND COMPANY (US) 1980-05-20 — — US disclosed
US-4144232-A Substituted azetidin-2-one antibiotics ELI LILLY AND COMPANY (US) 1979-03-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090005353-A1 Non-Anilinic Derivatives of Isothiazol-3(2H)-one 1,1-Dioxides as Liver X Receptor Modulators NR1H2, NR1H3, NR1I2 KDM4E 4359/4885GAA 2135/4885MAPT 2119/4885
US-11648220-B2 Methods for the treatment of myeloid derived suppressor cells related disorders NR1H3, NR1H2, MCL1 KDM4E 1602/4885GAA 2316/4885MAPT 3623/4885
US-20230338314-A1 METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS NR1H3, NR1H2, MCL1 KDM4E 1602/4885GAA 2316/4885MAPT 3623/4885
US-11691938-B2 Process for preparing 2,6-dialkylphenylacetic acids ADH1C, ADH1A, ADH5 KDM4E 2271/4885GAA 815/4885MAPT 4005/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.